Literature DB >> 23020312

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification.

Daisuke Miyaki1, Hiroshi Aikata, Yohji Honda, Noriaki Naeshiro, Takashi Nakahara, Mio Tanaka, Yuko Nagaoki, Tomokazu Kawaoka, Shintaro Takaki, Koji Waki, Akira Hiramatsu, Shoichi Takahashi, Masaki Ishikawa, Hideaki Kakizawa, Kazuo Awai, Kazuaki Chayama.   

Abstract

BACKGROUND AND AIM: We compared the treatment response, survival, and safety to hepatic arterial infusion chemotherapy (HAIC) in patients with advanced hepatocellular carcinoma (HCC) according to Child-Pugh (CP) score.
METHODS: The study subjects were 249 patients with advanced HCC and CP class A and B who had been treated with HAIC. Patients were grouped according to CP score (5/6, 7 and 8/9) and their tumor response, tolerance, and survival were assessed.
RESULTS: The median survival time (MST) was 8.2, 9.7, 6.3, and 3.9 months for the whole group, patients with CP 5/6, 7 and 8/9, respectively (P < 0.0001). Complete response (CR) and partial response (PR) were seen in 11 and 57 patients, respectively, with an overall response rate of 27.3%. The response rate was higher in patients with CP score 5/6 and 7, than CP 8/9 (30.5%, 28.2%, 13.8%). The dropout rate was significantly higher in patients with CP score 8/9 than the other two (8.0%, 12.8%, 33.3%, respectively). The survival rate was significantly better in patients who achieved CR/PR than the others with CP score 5/6, 7. CP score 8/9 was an independent negative factor for response and survival.
CONCLUSION: Advanced HCC patients with CP score of 5/6 and 7 showed a better response to HAIC and better prognosis than those with CP score 8/9.
© 2012 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23020312     DOI: 10.1111/j.1440-1746.2012.07276.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  22 in total

Review 1.  Current Status of Hepatic Arterial Infusion Chemotherapy.

Authors:  Shuntaro Obi; Shinpei Sato; Toshihiro Kawai
Journal:  Liver Cancer       Date:  2015-08-12       Impact factor: 11.740

2.  Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure.

Authors:  Tsung-Hao Liu; Chih-Hung Hsu; Yu-Yun Shao
Journal:  Liver Cancer       Date:  2018-04-20       Impact factor: 11.740

3.  Comparison of hepatic arterial infusion chemotherapy and sorafenib in elderly patients with advanced hepatocellular carcinoma: A case series.

Authors:  Tomoyuki Nemoto; Hidetaka Matsuda; Takuto Nosaka; Yasushi Saito; Yoshihiko Ozaki; Ryoko Hayama; Tatsushi Naito; Kazuto Takahashi; Kazuya Ofuji; Masahiro Ohtani; Katsushi Hiramatsu; Hiroyuki Suto; Yasunari Nakamoto
Journal:  Mol Clin Oncol       Date:  2014-08-05

4.  Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma.

Authors:  Kenji Oyama; Masahiko Koda; Takaaki Sugihara; Manabu Kishina; Kenichi Miyoshi; Toshiaki Okamoto; Masanori Hodotsuka; Yuki Fujise; Tomomitsu Matono; Shiho Tokunaga; Kinya Okamoto; Keiko Hosho; Junichi Okano; Yoshikazu Murawaki
Journal:  Mol Clin Oncol       Date:  2015-03-03

5.  Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients refractory to current treatments.

Authors:  Takahiro Yamasaki; Issei Saeki; Isao Sakaida
Journal:  Hepatol Int       Date:  2014-01-29       Impact factor: 6.047

Review 6.  Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update.

Authors:  Maher Hendi; Yiping Mou; Jiemin Lv; Bin Zhang; Xiujun Cai
Journal:  Gastrointest Tumors       Date:  2021-07-15

7.  Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.

Authors:  Kei Moriya; Tadashi Namisaki; Shinya Sato; Akitoshi Douhara; Masanori Furukawa; Hideto Kawaratani; Kosuke Kaji; Mitsuteru Kitade; Naotaka Shimozato; Yasuhiko Sawada; Kenichiro Seki; Soichiro Saikawa; Hiroaki Takaya; Takemi Akahane; Akira Mitoro; Yasushi Okura; Junichi Yamao; Hitoshi Yoshiji
Journal:  J Gastrointest Oncol       Date:  2018-08

8.  Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo.

Authors:  Yan Liu; Tingting Bi; Wei Dai; Gang Wang; Liqiang Qian; Quangen Gao; Genhai Shen
Journal:  Tumour Biol       Date:  2015-12-18

9.  Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases.

Authors:  Yuan Yan; Jie Li; Jia Han; Ni Hou; Ying Song; Lei Dong
Journal:  Anticancer Drugs       Date:  2015-06       Impact factor: 2.248

10.  A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy.

Authors:  Issei Saeki; Takahiro Yamasaki; Norikazu Tanabe; Takuya Iwamoto; Toshihiko Matsumoto; Yohei Urata; Isao Hidaka; Tsuyoshi Ishikawa; Taro Takami; Naoki Yamamoto; Koichi Uchida; Shuji Terai; Isao Sakaida
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.